1 September 2024
Shareholder Update May 2020
In this issue:
>> VivaGel® BV launched in Asia
>> Fleurstat BVgel launched in NZ
>> DEP® irinotecan phase 2 commences after positive phase 1 results
>> SPL7013 against SARS-COV-2 (coronavirus)
>> Fleurstat BVgel ranks as #1 topical BV treatment
>> Okamoto adds 11 more Asian countries to licence
>> US regulatory update
>> COVID-19: Starpharma’s operations continue with minimal disruption
>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
>> DEP® patient case studies
>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received
>> New DEP® ADC programs
>> DEP® pipeline targets multiple high-value areas
>> Other DEP® programs
>> Outlook, recent news & events
Download: Shareholder Update May 2020 (pdf file, 606kb)